Summary
Gilead Sciences, Inc. (GILD) announced the appointment of Kelly A. Kramer to its Board of Directors, effective August 19, 2016. Ms. Kramer will also serve on the Audit Committee. Her appointment is a procedural disclosure and does not involve any undisclosed arrangements or related party transactions. Investors should note that Ms. Kramer's compensation for her board service includes a pro-rated equity grant of stock options and restricted stock units, along with a pro-rated cash retainer. This appointment is primarily a governance update, with no immediate material impact on Gilead's operational or financial performance. The details of the compensation are consistent with typical director compensation structures, and further information on the company's equity incentive plan and director compensation practices can be found in previously filed public documents. The inclusion of a press release as an exhibit indicates the company's intent to publicly communicate this board change.
Key Highlights
- 1Kelly A. Kramer appointed to Gilead's Board of Directors, effective August 19, 2016.
- 2Ms. Kramer will serve as a member of the Board's Audit Committee.
- 3No undisclosed arrangements or related party transactions involving Ms. Kramer were reported.
- 4Ms. Kramer will receive pro-rated compensation for her director services.
- 5Compensation includes a pro-rated equity grant (stock options and RSUs) and a pro-rated cash retainer.
- 6Details of director compensation and equity plans are available in prior SEC filings.
- 7A press release announcing the appointment is attached as an exhibit.